Shanghai RAAS Blood Products Co Ltd Class A (002252) - Net Assets
Based on the latest financial reports, Shanghai RAAS Blood Products Co Ltd Class A (002252) has net assets worth CN¥32.52 Billion CNY (≈ $4.76 Billion USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥37.98 Billion ≈ $5.56 Billion USD) and total liabilities (CN¥5.46 Billion ≈ $798.84 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore 002252 total assets for the complete picture of this company's asset base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥32.52 Billion |
| % of Total Assets | 85.63% |
| Annual Growth Rate | 28.03% |
| 5-Year Change | 25.34% |
| 10-Year Change | 176.78% |
| Growth Volatility | 162.28 |
Shanghai RAAS Blood Products Co Ltd Class A - Net Assets Trend (2005–2025)
This chart illustrates how Shanghai RAAS Blood Products Co Ltd Class A's net assets have evolved over time, based on quarterly financial data. Check tangible equity quality of Shanghai RAAS Blood Products Co Ltd Clas to evaluate the tangible quality of the company's equity base.
Annual Net Assets for Shanghai RAAS Blood Products Co Ltd Class A (2005–2025)
The table below shows the annual net assets of Shanghai RAAS Blood Products Co Ltd Class A from 2005 to 2025. For live valuation and market cap data, see Shanghai RAAS Blood Products Co Ltd Clas (002252) total market value.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥32.47 Billion ≈ $4.75 Billion |
+1.65% |
| 2024-12-31 | CN¥31.94 Billion ≈ $4.67 Billion |
+7.73% |
| 2023-12-31 | CN¥29.65 Billion ≈ $4.34 Billion |
+2.90% |
| 2022-12-31 | CN¥28.81 Billion ≈ $4.22 Billion |
+11.23% |
| 2021-12-31 | CN¥25.90 Billion ≈ $3.79 Billion |
+3.08% |
| 2020-12-31 | CN¥25.13 Billion ≈ $3.68 Billion |
+118.69% |
| 2019-12-31 | CN¥11.49 Billion ≈ $1.68 Billion |
+5.42% |
| 2018-12-31 | CN¥10.90 Billion ≈ $1.60 Billion |
-12.66% |
| 2017-12-31 | CN¥12.48 Billion ≈ $1.83 Billion |
+6.39% |
| 2016-12-31 | CN¥11.73 Billion ≈ $1.72 Billion |
+9.50% |
| 2015-12-31 | CN¥10.71 Billion ≈ $1.57 Billion |
+24.21% |
| 2014-12-31 | CN¥8.62 Billion ≈ $1.26 Billion |
+682.76% |
| 2013-12-31 | CN¥1.10 Billion ≈ $161.22 Million |
+8.07% |
| 2012-12-31 | CN¥1.02 Billion ≈ $149.18 Million |
+9.94% |
| 2011-12-31 | CN¥927.27 Million ≈ $135.69 Million |
+11.56% |
| 2010-12-31 | CN¥831.21 Million ≈ $121.63 Million |
+8.89% |
| 2009-12-31 | CN¥763.33 Million ≈ $111.70 Million |
+1.14% |
| 2008-12-31 | CN¥754.76 Million ≈ $110.45 Million |
+343.95% |
| 2007-12-31 | CN¥170.01 Million ≈ $24.88 Million |
+8.44% |
| 2006-12-31 | CN¥156.77 Million ≈ $22.94 Million |
-32.34% |
| 2005-12-31 | CN¥231.70 Million ≈ $33.90 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Shanghai RAAS Blood Products Co Ltd Class A's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 7762.9% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥11.02 Billion | 33.96% |
| Common Stock | CN¥6.64 Billion | 20.45% |
| Other Comprehensive Income | CN¥1.12 Billion | 3.45% |
| Other Components | CN¥13.68 Billion | 42.14% |
| Total Equity | CN¥32.46 Billion | 100.00% |
Shanghai RAAS Blood Products Co Ltd Class A Competitors by Market Cap
The table below lists competitors of Shanghai RAAS Blood Products Co Ltd Class A ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Plains GP Holdings LP
NASDAQ:PAGP
|
$4.90 Billion |
|
NOVA LJUBLJ.BK GDR REG.S
F:N1V2
|
$4.90 Billion |
|
Hui Lyu Ecological Technology Groups Co Ltd
SHE:001267
|
$4.90 Billion |
|
Ecovacs Robotics Co Ltd
SHG:603486
|
$4.91 Billion |
|
Brown-Forman Corporation
NYSE:BF-A
|
$4.89 Billion |
|
United Tractors Tbk PT
JK:UNTR
|
$4.89 Billion |
|
Jiangsu Lettall Electronic Co Ltd
SHG:603629
|
$4.89 Billion |
|
PriceSmart Inc
NASDAQ:PSMT
|
$4.89 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Shanghai RAAS Blood Products Co Ltd Class A's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 31,926,258,696 to 32,456,025,360, a change of 529,766,664 (1.7%).
- Net income of 1,577,013,865 contributed positively to equity growth.
- Dividend payments of 317,875,597 reduced retained earnings.
- Share repurchases of 478,007,824 reduced equity.
- Other comprehensive income increased equity by 1,119,909,967.
- Other factors decreased equity by 1,371,273,747.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥1.58 Billion | +4.86% |
| Dividends Paid | CN¥317.88 Million | -0.98% |
| Share Repurchases | CN¥478.01 Million | -1.47% |
| Other Comprehensive Income | CN¥1.12 Billion | +3.45% |
| Other Changes | CN¥-1.37 Billion | -4.23% |
| Total Change | CN¥- | 1.66% |
Book Value vs Market Value Analysis
This analysis compares Shanghai RAAS Blood Products Co Ltd Class A's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.02x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 20.83x to 1.02x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2005-12-31 | CN¥0.24 | CN¥5.04 | x |
| 2006-12-31 | CN¥0.16 | CN¥5.04 | x |
| 2007-12-31 | CN¥0.06 | CN¥5.04 | x |
| 2008-12-31 | CN¥0.24 | CN¥5.04 | x |
| 2009-12-31 | CN¥0.22 | CN¥5.04 | x |
| 2010-12-31 | CN¥0.23 | CN¥5.04 | x |
| 2011-12-31 | CN¥0.26 | CN¥5.04 | x |
| 2012-12-31 | CN¥0.28 | CN¥5.04 | x |
| 2013-12-31 | CN¥0.29 | CN¥5.04 | x |
| 2014-12-31 | CN¥2.06 | CN¥5.04 | x |
| 2015-12-31 | CN¥2.15 | CN¥5.04 | x |
| 2016-12-31 | CN¥2.40 | CN¥5.04 | x |
| 2017-12-31 | CN¥2.53 | CN¥5.04 | x |
| 2018-12-31 | CN¥2.22 | CN¥5.04 | x |
| 2019-12-31 | CN¥2.27 | CN¥5.04 | x |
| 2020-12-31 | CN¥3.73 | CN¥5.04 | x |
| 2021-12-31 | CN¥3.84 | CN¥5.04 | x |
| 2022-12-31 | CN¥4.28 | CN¥5.04 | x |
| 2023-12-31 | CN¥4.50 | CN¥5.04 | x |
| 2024-12-31 | CN¥4.80 | CN¥5.04 | x |
| 2025-12-31 | CN¥4.94 | CN¥5.04 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Shanghai RAAS Blood Products Co Ltd Class A utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 4.86%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 21.46%
- • Asset Turnover: 0.19x
- • Equity Multiplier: 1.16x
- Recent ROE (4.86%) is below the historical average (13.38%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2005 | 22.14% | 16.90% | 0.91x | 1.44x | CN¥28.10 Million |
| 2006 | 32.41% | 18.20% | 0.86x | 2.08x | CN¥35.06 Million |
| 2007 | 48.66% | 26.38% | 1.01x | 1.82x | CN¥64.96 Million |
| 2008 | 13.95% | 33.82% | 0.37x | 1.11x | CN¥29.67 Million |
| 2009 | 17.88% | 35.01% | 0.47x | 1.09x | CN¥59.81 Million |
| 2010 | 22.51% | 38.38% | 0.52x | 1.13x | CN¥103.09 Million |
| 2011 | 21.91% | 35.31% | 0.56x | 1.10x | CN¥108.89 Million |
| 2012 | 22.42% | 33.96% | 0.55x | 1.20x | CN¥124.65 Million |
| 2013 | 13.23% | 28.97% | 0.32x | 1.45x | CN¥35.07 Million |
| 2014 | 5.93% | 38.71% | 0.14x | 1.09x | CN¥-350.12 Million |
| 2015 | 13.53% | 71.64% | 0.17x | 1.08x | CN¥376.57 Million |
| 2016 | 13.78% | 69.35% | 0.18x | 1.13x | CN¥442.28 Million |
| 2017 | 6.71% | 43.36% | 0.13x | 1.16x | CN¥-410.35 Million |
| 2018 | -13.95% | -84.16% | 0.16x | 1.05x | CN¥-2.61 Billion |
| 2019 | 5.30% | 23.52% | 0.22x | 1.03x | CN¥-539.98 Million |
| 2020 | 5.27% | 47.93% | 0.11x | 1.01x | CN¥-1.19 Billion |
| 2021 | 5.00% | 30.19% | 0.16x | 1.05x | CN¥-1.30 Billion |
| 2022 | 6.52% | 28.63% | 0.22x | 1.06x | CN¥-1.00 Billion |
| 2023 | 6.00% | 22.34% | 0.25x | 1.08x | CN¥-1.18 Billion |
| 2024 | 6.87% | 26.82% | 0.24x | 1.05x | CN¥-999.33 Million |
| 2025 | 4.86% | 21.46% | 0.19x | 1.16x | CN¥-1.67 Billion |
Industry Comparison
This section compares Shanghai RAAS Blood Products Co Ltd Class A's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,618,382,830
- Average return on equity (ROE) among peers: 5.03%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Shanghai RAAS Blood Products Co Ltd Class A (002252) | CN¥32.52 Billion | 22.14% | 0.17x | $4.90 Billion |
| Shenzhen CAU Technology Co Ltd (000004) | $85.28 Million | -13.04% | 0.97x | $9.88 Million |
| Pacific Shuanglin Bio pharmacy Co Ltd (000403) | $274.00 Million | 10.67% | 2.38x | $1.47 Billion |
| Nanhua Bio Medicine Co Ltd (000504) | $385.75 Million | 7.33% | 0.55x | $410.49 Million |
| Jiangsu Sihuan Bioengineering Co Ltd (000518) | $1.01 Billion | 0.71% | 0.21x | $628.24 Million |
| Chengzhi Shareholding Co Ltd (000990) | $129.07 Million | 18.02% | 0.66x | $1.20 Billion |
| Hualan Biological EngineeringInc (002007) | $2.58 Billion | 14.36% | 0.06x | $3.59 Billion |
| Da An Gene Co Ltd of Sun Yat-Sen University (002030) | $7.36 Billion | -10.11% | 0.16x | $1.15 Billion |
| Baolingbao Biology Co Ltd (002286) | $1.53 Billion | 3.25% | 0.38x | $445.51 Million |
| Tibet Cheezheng Tibetan Medicine Co Ltd (002287) | $1.21 Billion | 14.10% | 0.09x | $1.76 Billion |
About Shanghai RAAS Blood Products Co Ltd Class A
Shanghai RAAS Blood Products Co., Ltd., together with its subsidiaries, produces and sells blood products in China and internationally. The company offers ALBURAAS, which is albumin prepared from human plasma; GAMARAAS, a human immunoglobulin product for intravenous injections; HEMORAAS, a human coagulation factor VIII product; PROTHORAAS, a human prothrombin complex; FIBRORAAS, a human fibrinoge… Read more